BRPI0918508A2 - orto-aminoanilidas para o tratamento de câncer - Google Patents

orto-aminoanilidas para o tratamento de câncer

Info

Publication number
BRPI0918508A2
BRPI0918508A2 BRPI0918508A BRPI0918508A BRPI0918508A2 BR PI0918508 A2 BRPI0918508 A2 BR PI0918508A2 BR PI0918508 A BRPI0918508 A BR PI0918508A BR PI0918508 A BRPI0918508 A BR PI0918508A BR PI0918508 A2 BRPI0918508 A2 BR PI0918508A2
Authority
BR
Brazil
Prior art keywords
aminoanilides
ortho
cancer treatment
cancer
treatment
Prior art date
Application number
BRPI0918508A
Other languages
English (en)
Inventor
Chungen Liang
Guozhi Tang
Jason Christopher Wong
Xihan Wu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0918508A2 publication Critical patent/BRPI0918508A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/80—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0918508A 2008-09-17 2009-09-07 orto-aminoanilidas para o tratamento de câncer BRPI0918508A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08164509 2008-09-17
PCT/EP2009/061533 WO2010031708A2 (en) 2008-09-17 2009-09-07 Novel ortho-aminoanilides for the treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0918508A2 true BRPI0918508A2 (pt) 2015-12-08

Family

ID=41716278

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918508A BRPI0918508A2 (pt) 2008-09-17 2009-09-07 orto-aminoanilidas para o tratamento de câncer

Country Status (13)

Country Link
US (1) US8202866B2 (pt)
EP (1) EP2334658A2 (pt)
JP (1) JP2011526936A (pt)
KR (1) KR20110043767A (pt)
CN (1) CN102149678A (pt)
AR (1) AR073513A1 (pt)
AU (1) AU2009294668A1 (pt)
BR (1) BRPI0918508A2 (pt)
CA (1) CA2734349A1 (pt)
IL (1) IL210066A0 (pt)
MX (1) MX2011002574A (pt)
TW (1) TWI378093B (pt)
WO (1) WO2010031708A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009289649B2 (en) 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
WO2012118782A1 (en) 2011-02-28 2012-09-07 Repligen Corporation Histone deacetylase inhibitors
US8781041B2 (en) * 2012-07-31 2014-07-15 Hewlett-Packard Development Company, L.P. Reducing noise in a sequence of data by linear and non-linear estimation
RU2665554C2 (ru) 2013-03-15 2018-08-31 Байомарин Фармасьютикал Инк. Ингибиторы hdac

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1643264A1 (de) * 1967-12-20 1971-06-09 Basf Ag Verfahren zur Herstellung von Aminoaniliden
IT1033046B (it) 1970-10-31 1979-07-10 Finotto Martino Procedimento di fabbricazione di benzimidazoli sostituiti
CA2465978C (en) * 2001-09-14 2015-04-07 Soon Hyung Woo Inhibitors of histone deacetylase
AU2007208495A1 (en) 2006-01-12 2007-08-02 Merck Sharp & Dohme Corp. Hydroxyalkylarylamide derivatives
US8168658B2 (en) 2006-02-28 2012-05-01 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase
JP2010513326A (ja) * 2006-12-19 2010-04-30 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害薬及びそのプロドラッグ
WO2008087514A2 (en) * 2007-01-17 2008-07-24 Orchid Research Laboratories Limited Hdac inhibitors
WO2009095324A1 (en) * 2008-01-29 2009-08-06 F. Hoffmann-La Roche Ag Novel n-(2-amino-phenyl)-amide derivatives
MX2010012297A (es) * 2008-05-16 2010-12-06 Hoffmann La Roche Nuevas n-(2-amino-fenil)-acrilamidas.
JP2011150917A (ja) * 2010-01-22 2011-08-04 Nippon Soken Inc ガス拡散層およびそれを備える燃料電池

Also Published As

Publication number Publication date
CN102149678A (zh) 2011-08-10
KR20110043767A (ko) 2011-04-27
US20100069328A1 (en) 2010-03-18
EP2334658A2 (en) 2011-06-22
AU2009294668A1 (en) 2010-03-25
WO2010031708A2 (en) 2010-03-25
TW201014834A (en) 2010-04-16
MX2011002574A (es) 2011-04-26
JP2011526936A (ja) 2011-10-20
IL210066A0 (en) 2011-02-28
WO2010031708A3 (en) 2010-08-05
CA2734349A1 (en) 2010-03-25
AR073513A1 (es) 2010-11-10
TWI378093B (en) 2012-12-01
US8202866B2 (en) 2012-06-19

Similar Documents

Publication Publication Date Title
BR112012005594A2 (pt) tratamento de câncer
BRPI0810206A2 (pt) Método de tratar câncer
BRPI0922884A2 (pt) compostos para tratamento de câncer
PT2340042E (pt) Métodos e composições para o tratamento de cancro
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
DK2121139T3 (da) Formulations for cancer treatment
BRPI1015215A2 (pt) porções de ligação alvo armadas com amatoxina para o tratamento de câncer
BRPI0910282A2 (pt) Composto oxadiazo-antraceno para o tratamento de diabetes
BRPI0818320A2 (pt) composição para tratamento de câncer de próstata (pca)
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI1010874A8 (pt) composição para o tratamento de câncer de próstata
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0813670A2 (pt) Compostos para tratamento
BRPI0910854A2 (pt) métodos de tratamento
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI1009919A2 (pt) combinações de pentamidina para tratamento de câncer.
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BR112012000502A2 (pt) terapia de combinação para o tratamento de diabetes
EP2283862A4 (en) CANCER AGENT
BRPI0908715A2 (pt) métodos para tratamento da psoríase
BR112012002797A2 (pt) tratamento de câncer de próstata
BR112012000098A2 (pt) Processo para identificação de compostos para tratar câncer
BRPI0812040A2 (pt) Indicações para terapia de anti-il-i-beta

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.